Loading clinical trials...

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNANCT00080873

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

RATIONALE: Traumeel® S (a mouth rinse) may be effective in preventing or decreasing the severity of oral mucositis caused by chemotherapy in young patients who are undergoing stem cell transplantation...

Lead sponsor: Children's Oncology Group•37 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

RECRUITINGPhase 1

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

NCT06191978 · Acute Myeloid Leukemia

RECRUITINGPhase 2

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

NCT06317649 · Acute Myeloid Leukemia

RECRUITINGPhase 1/2

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more

RECRUITINGPhase 2

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

NCT06311227 · Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant

RECRUITINGPhase 3

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 7, 2016Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment195

Start dateApr 2004

Last updatedJan 7, 2016

Condition

Kidney Cancer Leukemia Lymphoma Neuroblastoma Oral Complications+1 more

Locations shown

University of Alabama at Birmingham Comprehensive Cancer Center

Birmingham, Alabama

Jonsson Comprehensive Cancer Center at UCLA

Los Angeles, California

Children's Hospital of Orange County

Orange, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 7, 2016Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions